{"protocolSection":{"identificationModule":{"nctId":"NCT00753896","orgStudyIdInfo":{"id":"H8O-MC-GWDC"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin","officialTitle":"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin"},"statusModule":{"statusVerifiedDate":"2015-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-10"},"primaryCompletionDateStruct":{"date":"2009-07","type":"ACTUAL"},"completionDateStruct":{"date":"2009-11","type":"ACTUAL"},"studyFirstSubmitDate":"2008-09-15","studyFirstSubmitQcDate":"2008-09-15","studyFirstPostDateStruct":{"date":"2008-09-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-02-14","resultsFirstSubmitQcDate":"2012-02-14","resultsFirstPostDateStruct":{"date":"2012-03-20","type":"ESTIMATED"},"dispFirstSubmitDate":"2010-08-13","dispFirstSubmitQcDate":"2010-08-13","dispFirstPostDateStruct":{"date":"2010-08-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-04-20","lastUpdatePostDateStruct":{"date":"2015-04-21","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"},"collaborators":[{"name":"Eli Lilly and Company","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will examine the safety of exenatide once weekly (2.0 mg) in approximately 134 patients receiving treatment with thiazolidinedione alone or thiazolidinedione in combination with metformin. Patients are expected to be treated with exenatide once weekly for at least 52 weeks."},"conditionsModule":{"conditions":["Type 2 Diabetes"],"keywords":["Amylin","Lilly","exenatide once weekly","thiazolidinedione","metformin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":134,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide"]}],"interventions":[{"type":"DRUG","name":"exenatide","description":"subcutaneous injection, 2.0mcg, once weekly","armGroupLabels":["1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Patients Experiencing Adverse Events","description":"Percentage of patients experiencing treatment-emergent adverse events over 52 weeks","timeFrame":"Baseline to Week 52"},{"measure":"Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events","description":"Major hypoglycemia: any episode with symptoms consistent with hypoglycemia that resulted in loss of consciousness or seizure with prompt recovery in response to administration of glucagon or glucose OR documented hypoglycemia (blood glucose \\<3.0 mmol/L \\[54 mg/dL\\]) and required the assistance of another person. Minor hypoglycemia: any sign or symptom associated with hypoglycemia that is either self-treated by the patient or resolves on its own AND has a concurrent finger stick blood glucose \\<3.0 mmol/L (54 mg/dL) and not classified as major hypoglycemia. Mean event rate = total number of events for all subjects in a treatment regimen / the total number of subject years of exposure for all subjects in that treatment. Standard error = square root of (total number of events / (subject years of exposure)\\*\\*2).","timeFrame":"Baseline to Week 52"}],"secondaryOutcomes":[{"measure":"Change in HbA1c From Baseline to Week 52","description":"Change in HbA1c from baseline to endpoint","timeFrame":"Baseline, Week 52"},{"measure":"Percentage of Patients Achieving HbA1c <=7% at Week 52","description":"Percentage of patients achieving HbA1c \\<=7% at endpoint (for patients with HbA1c \\>7% at baseline)","timeFrame":"Baseline, Week 52"},{"measure":"Percentage of Patients Achieving HbA1c <=6.5% at Week 52","description":"Percentage of patients achieving HbA1c \\<=6.5% at endpoint (for patients with HbA1c \\>6.5% at baseline)","timeFrame":"Baseline, Week 52"},{"measure":"Change in Fasting Serum Glucose From Baseline to Week 52","description":"Change in fasting serum glucose from baseline to endpoint","timeFrame":"Baseline, Week 52"},{"measure":"Change in Body Weight From Baseline to Week 52","description":"Change in body weight from baseline to endpoint","timeFrame":"Baseline, Week 52"},{"measure":"Change in Total Cholesterol From Baseline to Week 52","description":"Change in Total Cholesterol from baseline to endpoint","timeFrame":"Baseline, Week 52"},{"measure":"Change in High-density Lipoprotein (HDL) From Baseline to Week 52","description":"Change in HDL from baseline to endpoint","timeFrame":"Baseline, Week 52"},{"measure":"Change in Triglycerides From Baseline to Week 52","description":"Change in Triglycerides from baseline to endpoint","timeFrame":"Baseline, Week 52"},{"measure":"Change in Blood Pressure From Baseline to Week 52","description":"Change in Systolic and Diastolic Blood Pressure from baseline to endpoint","timeFrame":"Baseline, Week 52"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have type 2 diabetes\n* At least 18 years of age at screening.\n* Have HbA1c of 7.1% to 10.0%, inclusive, at screening.\n* Have a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive.\n* Have been treated with a stable dose of TZD (≥4 mg/day rosiglitazone or ≥30 mg/day pioglitazone) for at least 120 days prior to Visit 1 OR Have been treated with a stable dose of TZD (≥4 mg/day rosiglitazone or ≥30 mg/day pioglitazone) for at least 120 days PLUS a stable dose of metformin for at least 90 days prior to Visit 1.\n* Have a history of stable body weight (not varying by \\>10% for at least 3 months prior to screening).\n* If female of child-bearing potential (not surgically sterilized and between menarche and 1-year postmenopause) only.\n\n  * Are not breastfeeding.\n  * Test negative for pregnancy at the time of screening based on a serum pregnancy test.\n  * Intend not to become pregnant during the study.\n  * Have practiced a reliable method of birth control (e.g., use of oral contraceptives or approved hormonal implant; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for at least 6 weeks prior to screening.\n  * Agree to continue to use a reliable method of birth control (see above) during the study.\n\nExclusion Criteria:\n\n* Have had a clinically significant history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study, including myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, angioplasty.\n* Is expected to require coronary artery bypass surgery or angioplasty during the course of the study.\n* Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis\n* Have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine ≥135 μmol/L for males and ≥110 μmol/L for females.\n* Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.\n* Have known hemoglobinopathy or chronic anemia (hemoglobin concentration \\<11.5 g/dL \\[115 g/L\\] for males, \\<10.5 g/dL \\[105 g/L\\] for females).\n* Have clinically significant history or presence of severe gastrointestinal disease, particularly those which may impact gastric emptying, such as gastroparesis, pyloric stenosis, or gastric bypass surgery.\n* Have a history of pancreatitis.\n* Have had greater than three episodes of major hypoglycemia within 6 months prior to screening.\n* Have any contraindication for the OAD(s) which they use, according to local label requirements.\n* Are known to have active proliferative retinopathy.\n* Are receiving chronic (\\>2 weeks) systemic glucocorticoid therapy (excluding topical or inhaled preparations) or have received systemic glucocorticoid therapy for \\>2 weeks within the 4 weeks immediately preceding screening.\n* Have been treated with drugs that promote weight loss (e.g., Xenical® \\[orlistat\\], Meridia® \\[sibutramine\\], Acomplia® \\[rimonabant\\], Acutrim® \\[phenylpropanolamine\\], or similar over-the-counter medications) within 3 months of screening.\n* Have previously been treated with glucagon-like peptide 1 analogs or liraglutide.\n* Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening: Insulin; Sulfonylureas; Alpha-glucosidase inhibitors (e.g., Glyset® \\[miglitol\\] or Precose® \\[acarbose\\]); Meglitinides (e.g., Prandin® \\[repaglinide\\] or Starlix® \\[nateglinide\\]); Dipeptidyl peptidase (DPP)-4 inhibitors (e.g., Januvia™ \\[sitagliptin\\], Galvus® \\[vildagliptin\\]); Symlin® (pramlintide acetate).\n* Have had an organ transplant.\n* Have donated blood within 30 days of screening.\n* Have previously completed or withdrawn from this study or any other study investigating exenatide once weekly.\n* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.\n* Are currently participating in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment is given). Patients completing the final visit of a study examining safety/efficacy of exenatide BID may enter this study on the same day if they meet other eligibility criteria.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Chief Medical Officer, MD","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Mesa","state":"Arizona","country":"United States","geoPoint":{"lat":33.42227,"lon":-111.82264}},{"facility":"Research Site","city":"Tempe","state":"Arizona","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"Research Site","city":"Concord","state":"California","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"Research Site","city":"Fresno","state":"California","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"Research Site","city":"La Mesa","state":"California","country":"United States","geoPoint":{"lat":32.76783,"lon":-117.02308}},{"facility":"Research Site","city":"Atlanta","state":"Georgia","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Research Site","city":"Idaho Falls","state":"Idaho","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"Research Site","city":"Bowling Green","state":"Kentucky","country":"United States","geoPoint":{"lat":36.99032,"lon":-86.4436}},{"facility":"Research Site","city":"Corvallis","state":"Oregon","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Research Site","city":"Chattanooga","state":"Tennessee","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Research Site","city":"Memphis","state":"Tennessee","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Research Site","city":"New Westminster","state":"British Columbia","country":"Canada","geoPoint":{"lat":49.20678,"lon":-122.91092}},{"facility":"Research Site","city":"Ajax","state":"Ontario","country":"Canada","geoPoint":{"lat":43.85012,"lon":-79.03288}},{"facility":"Research Site","city":"Cambridge","state":"Ontario","country":"Canada","geoPoint":{"lat":43.3601,"lon":-80.31269}},{"facility":"Research Site","city":"Windsor","state":"Ontario","country":"Canada","geoPoint":{"lat":42.30008,"lon":-83.01654}},{"facility":"Research Site","city":"Chihuahua City","state":"Chiuahua","country":"Mexico","geoPoint":{"lat":28.63528,"lon":-106.08889}},{"facility":"Research Site","city":"Monterrey","state":"Nuevo León","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Research Site","city":"Distrito Federal","country":"Mexico","geoPoint":{"lat":16.59,"lon":-93.02694}},{"facility":"Research Site","city":"Baia Mare","country":"Romania","geoPoint":{"lat":47.65729,"lon":23.56808}},{"facility":"Research Site","city":"Brasov","country":"Romania","geoPoint":{"lat":45.64861,"lon":25.60613}},{"facility":"Research Site","city":"Bucharesti","country":"Romania"},{"facility":"Research Site","city":"Craiova","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Research Site","city":"Iași","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"Research Site","city":"Suceava","country":"Romania","geoPoint":{"lat":47.63333,"lon":26.25}},{"facility":"Research Site","city":"Johannesburg","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Research Site","city":"Pretoria","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}}]},"referencesModule":{"references":[{"pmid":"23031623","type":"DERIVED","citation":"Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012 Oct;34(10):2082-90. doi: 10.1016/j.clinthera.2012.09.007. Epub 2012 Sep 29."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"134"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"118"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Entry Criteria Not Met","reasons":[{"groupId":"FG000","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"134"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"114"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"20"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.0","spread":"9.74"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"60"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"74"}]}]}]},{"title":"Glycosylated hemoglobin (HbA1c)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"percentage of total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7.2","spread":"0.95"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"98.1","spread":"18.71"}]}]}]},{"title":"Background Oral Antidiabetic Agent","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Metformin + Thiazolidinedione (TZD)","categories":[{"measurements":[{"groupId":"BG000","value":"118"}]}]},{"title":"TZD","categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Experiencing Adverse Events","description":"Percentage of patients experiencing treatment-emergent adverse events over 52 weeks","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Sample size based on FDA recommendation for safety exposure: a minimum of 100 patients completing at least 52 weeks of treatment is sought to assess long-term safety associated with exposure to exenatide once weekly.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of patients","timeFrame":"Baseline to Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1"}]}]}]},{"type":"PRIMARY","title":"Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events","description":"Major hypoglycemia: any episode with symptoms consistent with hypoglycemia that resulted in loss of consciousness or seizure with prompt recovery in response to administration of glucagon or glucose OR documented hypoglycemia (blood glucose \\<3.0 mmol/L \\[54 mg/dL\\]) and required the assistance of another person. Minor hypoglycemia: any sign or symptom associated with hypoglycemia that is either self-treated by the patient or resolves on its own AND has a concurrent finger stick blood glucose \\<3.0 mmol/L (54 mg/dL) and not classified as major hypoglycemia. Mean event rate = total number of events for all subjects in a treatment regimen / the total number of subject years of exposure for all subjects in that treatment. Standard error = square root of (total number of events / (subject years of exposure)\\*\\*2).","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Sample size based on FDA recommendation for safety exposure: a minimum of 100 patients completing at least 52 weeks of treatment is sought to assess long-term safety associated with exposure to exenatide once weekly.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"events per subject-year","timeFrame":"Baseline to Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"classes":[{"title":"Major Hypoglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"title":"Minor Hypoglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 52","description":"Change in HbA1c from baseline to endpoint","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of total hemoglobin","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving HbA1c <=7% at Week 52","description":"Percentage of patients achieving HbA1c \\<=7% at endpoint (for patients with HbA1c \\>7% at baseline)","populationDescription":"All enrolled patients who had taken at least one dose of study drug and whose baseline HbA1c was \\> 7% . Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of patients","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving HbA1c <=6.5% at Week 52","description":"Percentage of patients achieving HbA1c \\<=6.5% at endpoint (for patients with HbA1c \\>6.5% at baseline)","populationDescription":"All enrolled patients who had taken at least one dose of study drug and whose baseline HbA1c was \\> 6.5%. Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of patients","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Glucose From Baseline to Week 52","description":"Change in fasting serum glucose from baseline to endpoint","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mmol/L","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 52","description":"Change in body weight from baseline to endpoint","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol From Baseline to Week 52","description":"Change in Total Cholesterol from baseline to endpoint","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mmol/L","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in High-density Lipoprotein (HDL) From Baseline to Week 52","description":"Change in HDL from baseline to endpoint","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mmol/L","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides From Baseline to Week 52","description":"Change in Triglycerides from baseline to endpoint","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mmol/L","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change in Blood Pressure From Baseline to Week 52","description":"Change in Systolic and Diastolic Blood Pressure from baseline to endpoint","populationDescription":"All enrolled patients who had taken at least one dose of study drug. Last observation carried forward. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mmHg","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"}]}],"classes":[{"title":"Systolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"-1.69","spread":"1.12"}]}]},{"title":"Diastolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.70"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Exenatide Once Weekly","description":"Subcutaneous injection, 2.0mcg, once weekly.","seriousNumAffected":9,"seriousNumAtRisk":134,"otherNumAffected":67,"otherNumAtRisk":134}],"seriousEvents":[{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Anorectal cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Brain neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Calculus urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Colon cancer stage II","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Patella fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":134}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":134}]},{"term":"Injection site nodule","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":134}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":134}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":134}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":134}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":134}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":134}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":134}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":134}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":134}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":134}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":134}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Peter Ohman, Medical Science Director","organization":"AstraZeneca","email":"ClinicalTrialTransparency@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077270","term":"Exenatide"}],"ancestors":[{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014688","term":"Venoms"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D014118","term":"Toxins, Biological"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}